Glioma: immunotherapeutic approaches
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
New York, NY
Springer [u.a.]
2012
|
| Schriftenreihe: | Advances in experimental medicine and biology
746 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XIX, 232 S. Ill., graph. Darst. |
| ISBN: | 9781461431459 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV040154757 | ||
| 003 | DE-604 | ||
| 005 | 20120711 | ||
| 007 | t | ||
| 008 | 120525s2012 ad|| |||| 00||| eng d | ||
| 020 | |a 9781461431459 |9 978-1-4614-3145-9 | ||
| 035 | |a (OCoLC)796245945 | ||
| 035 | |a (DE-599)BVBBV040154757 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 |a DE-12 |a DE-20 | ||
| 084 | |a XH 8565 |0 (DE-625)152960:13144 |2 rvk | ||
| 245 | 1 | 0 | |a Glioma |b immunotherapeutic approaches |c ed. by Ryuya Yamanaka |
| 264 | 1 | |a New York, NY |b Springer [u.a.] |c 2012 | |
| 300 | |a XIX, 232 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Advances in experimental medicine and biology |v 746 | |
| 650 | 0 | 7 | |a Gliom |0 (DE-588)4157618-4 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Immuntherapie |0 (DE-588)4026640-0 |2 gnd |9 rswk-swf |
| 655 | 7 | |8 1\p |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Gliom |0 (DE-588)4157618-4 |D s |
| 689 | 0 | 1 | |a Immuntherapie |0 (DE-588)4026640-0 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Yamanaka, Ryuya |e Sonstige |4 oth | |
| 830 | 0 | |a Advances in experimental medicine and biology |v 746 |w (DE-604)BV000003102 |9 746 | |
| 856 | 4 | 2 | |m Digitalisierung UB Regensburg |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025011410&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-025011410 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
Datensatz im Suchindex
| _version_ | 1804149181539942400 |
|---|---|
| adam_text | CONTENTS
PART I. BASIC AND CLINICAL
ASPECT OF
GLIOMA
1.
MOLECULAR BIOLOGY OF
GLIOMA
..............................................................2
Tomotoshi Marumoto and Hideyuki
Saya
Abstract
..................·■.................................»...«*.........................................................····...............2
Tntroduction
■.■■■.»■■...■.... ■■.■■■.■■■■■*■.... .■■■■■■.■■.■■.. ■■...■■... >■■·■■■.■■■■■·■··■· 2
Primary and Secondary GBMs
...................................................................................................3
Activated Growth Factor Signaling Pathways
..........................................................................3
Deregulation of Cell Cycle Checkpoints
...................................................................................4
Isocitrate
Dehydrogenase
1
(IDH1) and IDH2 Mutations in GBMs
.......................................5
Aberrant Functions of MicroRNAs in GBM
.............................................................................6
Drug Resistance in GBM
.............................................................................................................7
Conclusion
......·......·............·..................
•■».φ....·.........·
......
ΦΦΦΦΦΦΦ·
.......
.ΦΦΦΦ.ΦΦΦΦΦΦΦΦΦΦΦΦ
......................·.....8
2.
RECENT SURGICAL MANAGEMENT OF GLIOMAS
..................................12
Nader
Sanai
and Mitchel
S. Berger
Abstract
.......................................................................................................................................12
Introduction
................................................................................................................................12
The Evolution of Cortical Mapping Strategies
.......................................................................13
Variability in Cortical Language Localization
........................................................................14
Avoidance of Functional Language Deficits following Awake Mapping
...............................14
Patient Selection and the Role of Functional Imaging for Language Localization
.............15
Specialized Neuroanesthesia for the Awake Craniotomy
.......................................................15
Current
Intraoperative
Language Mapping Techniques
.......................................................16
Functional Outcome following Language Mapping for Dominant
Hemisphere Gliomas
..........................................................................................................16
Tailored Craniotomies and the Value of Negative Language Mapping
................................17
An Evidence-Based Approach to Understanding the Value of Extent of Resection
............19
Conclusion
..................................................................................................................................21
xiii
xiv CONTENTS
3.
RECENT MEDICAL MANAGEMENT
OF
GLIOBLASTOMA....
..................26
Derek
R.
Johnson and
Susan
M.
Chang
Abstract
.......................................................................................................................................26
Introduction.......·....
........................................*......,..................................··............·................... 26
Cytotoxic Chemotherapy for Glioblastoma
Multiforme
........................................................27
Molecularly Targeted Therapies for Glioblastoma
Multiforme
............................................30
Conclusion
..................................................................................................................................36
PART II.
GLIOMA
IMMUNOLOGY
4.
BASIC CONCEPTS IN
GLIOMA
IMMUNOLOGY.
.........................................42
Ian F. Pamey
Abstract
.......................................................................................................................................42
Introduction.....
......................................·....·..........,.·.....·............................................................ 42
Basic Immunology
......................................................................................................................43
Neuro-Immunology
....................................................................................................................44
Glioblastoma-Associated Antigens
...........................................................................................45
Glioblastoma-Derived Immunosuppressive Factors
...............................................................46
Modulation of Local Immune Response by Glioblastoma-Infiltrating Cells
__...................47
Systemic Immunosuppression in Glioblastoma Patients
........................................................ 47
Towards a Unified Model of Glioblastoma-Mediated Immunosuppression
.........................48
Conclusion
..................................................................................................................................49
5.
MECHANISMS OF IMMUNE EVASION BY GLIOMAS
................................53
Cleo
E.
Rolle,
Sadhak Sengupta and
Maciej
S.
Lesniak
Abstract
.......................................................................................................................................53
Introduction
................................................................................................................................ 53
Intrinsic Mechanisms of Immunosuppression
........................................................................ 54
Impairment of
Glioma
and Immune Cell Interactions
..........................................................57
Mechanisms of Glioma-Mediated Immunosuppression
.........................................................57
Recruitment of Immunosuppressive Lymphocytes
.................................................................64
Conclusion
......................................................................................*........................................... 68
6.
GLIOMA
ANTIGEN
..............................................................................................77
MasahiroToda
Abstract........
...............................................................................................................................77
Introduction....
....................·...........................................···....···........·.·.........·............................. 77
Tumor Antigens Recognized by CTLs....
___...__.___.____.__.___.------.______.___.......78
Direct Identification of Antigenic
Peptide
Using CTLs
.......................................................... 78
Identification of Tumor Antigen by cDNA Expression Cloning Using CTLs
.......................79
Identification of Tumor Antigens from Candidate Molecules
without Using CTLs (Reverse Immunology)
...................................................................79
CONTENTS xv
fuliniti
я
ÀntitTpnS
........... .......................... ... ........ ........... ....................... 79
Glioma
Antigens Identified Using SEREX
..............................................................................80
Glioma
Antigens Recognized by CTLs
....................................................................................81
Glioma
Antigens Recognized by Antibodies
............................................................................82
Neural Stem Cells and
Glioma
Antigens
..................................................................................82
■■.■■■■■■■■.. .·■.■■·■■■.■■■.···■■■■■.■■■■.·■··■·■■■■. .... . ■■■■■. ■ ■■■■■..■■. .....■■■... ■■■■■■■■.. 82
PART III. CYTOKINE, SEROTHERAPY, ADOPTIVE
TRANSFER
AND OTHER STRATEGIES
7.
CYTOKINE
THERAPY
........................................................................................86
Masasuke
Ohno,
Atsushi Natsume and
Toshihiko
Wakabayashi
Abstract
.......................................................................................................................................86
Introduction.
.................................................·...................................................86
IL-2
..............................................................................................................................................87
IL-4
_____________._______._____...._____________________.____________________88
IL-13
............................................................................................................................................89
XGF-ß..........................................................................................................................................89
GM-CSF
......................................................................................................................................90
IFN-ß...........................................................................................................................................91
Conclusion
..................................................................................................................................92
8.
IMMUNOTHERAPEUTIC
APPROACH
WITH OLIGODEOXYNUCLEOTIDES CONTAINING
CpG MOTIFS (CpG-ODN) IN MALIGNANT
GLIOMA
..........................95
Renata
Ursu and
Antoine F. Carpentier
Abstract.......................................................................................................................................
95
Introduction
................................................................................................................................95
CpG
Motifs
.................................................................................................................................96
Rationale
for CpG-ODNs
in
Gliomas
and Preclinical Data
...................................................98
Clinical
Development
of CpG-ODNs in Cancer and in Brain Tumors
.................................99
Perspectives in Clinical Trials
.................................................................................................104
Tolerance
...................................................................................................................................104
Conclusion
................................................................................................................................105
9.
ADOPTIVE CELL TRANSFER THERAPY
FOR MALIGNANT GLIOMAS
.................................................................109
Eiichi Ishikawa, Shingo
Takáno,
Tadao Ohno and
Koji Tsuboi
Abstract
.....................................................................................................................................109
Introduction
..............................................................................................................................110
Nonspecific Immune Cell Therapy
..........................................................................................
Ill
TXimor-Specific Immune Cell Therapy
...................................................................................113
Conclusion
................................................................................................................................118
xvi CONTENTS
10.
MONOCLONAL ANTIBODY THERAPY
FOR MALIGNANT
GLIOMA
....................................................................121
Kevin S. Chen and Duane A. Mitchell
Abstract
.....................................................................................................................................121
Introduction
..............................·.............
..........φ.....·....
..............·....,........·.,..............................121
Antibody CNS Bioavailability
.................................................................................................122
Delivery of Antibody Therapy
................................................................................................123
Unarmed Antibodies
.........................................................................................................,......124
Radioisotope
or Toxin Conjugated Antibodies
......................................................................127
Immunotherapy Modulators....................
..............................................................................129
Antibody-Based Innovations in Immunotherapy
.............................................................__131
Conclusion
................................................................................................................................133
PART IV. ACTIVE IMMUNOTHERAPY
11.
ANIMAL MODELS FOR VACCINE THERAPY
_______...............................143
Dong-Sup Chung, Chang-Hyun Kim and Yong-Kil Hong
Abstract
.....................................................................................................................................143
Introduction......................................
........................................................................................143
Transplantable Tumor Models
................................................................................................144
Spontaneous Tumor Models
....................................................................................................145
Monitoring of the Animal Tumors
..................................____.____.......................................146
Monitoring of the Immune Function in Animal Models
......................................................147
Chemoimmunotherapy in GL26
Glioma
Model
...................................................................147
Conclusion
...........................................................................................................*..............···*.. 148
12.
IMMUNOGENE THERAPY
.............................................................................151
Terry Lichtor and Roberta P. Glick
Abstract
.....................................................................................................................................151
Introduction
............................................·■··.............................................···....···.......................152
Preclinical Experimental Findings
.........................................................................................157
Conclusion
................................................................................................................................161
13.
PEPTIDE
VACCINE
..........................................................................................166
Shuichi Izumoto
Abstract
.....................................................................................................................................166
Introduction
................··.·..........*......·.............··.............··......·..·■··.....··....···.....·.·...··■·....·........··. 166
Peptide-Based Vaccines
...........................................................................................................167
WTl-Peptide Vaccination
........................................................................................................167
Personalized
Peptide
Vaccination
...........................................................................................171
EGFRvIII
Peptide
Vaccination
________________________________________________172
Hurdles to Effective
Peptide
Vaccine..
...................................................................................173
CONTENTS
ïvii
Enhancement
of
Clinicai
Efficacy and Usefulness of
Peptide
Vaccine
................................174
Evaluation of
Peptide
Vaccine-Induced Clinical Responses
................................................174
.............................■■.........................■...■■..■.■..■■.....■.......■■■■■■■■■■■■■.■■.■■........ 174
14.
ACTIVE IMMUNOTHERAPY:
ONCOLYTIC VIRUS THERAPY USING HSV-1
.....................................178
Tomoki
Todo
Λ
h«
tract
..............................................................................................................................178
Tnŕrnrliiftinn
............................................................................................................178
Genetically Engineered
Oncolytic HSV-1
..............................................................................179
Third-Generation
Oncolytic HSV-1
................................................,......................................180
Induction of Specific
Antitumor
Immunity by Oncolytic HSV-1
........................................180
Oncolytic HSV-1 in Combination with Immune Gene Therapy
..........................................181
Oncolytic HSV-1 Armed with Immunostimulatory Genes
...................................................182
Utilization of Armed Oncolytic HSV-1 Construction Systems
.............................................182
Systemic Delivery of Armed Oncolytic HSV-1
......................................................................184
Conclusion
..·...·..·......···...........■·....■■·......··>·...·.·...................····..·............................................... 184
15.
DENDRITIC CELL VACCINES
.......................................................................187
Ryuya Yamanaka and
Koji
Kajiwara
Abstract
.....................................................................................................................................187
Introduction
..............................................................................................................................187
Dendritic Cells in Immunobiology
.........................................................................................188
Dendritic Cells in the Central Nervous System
.....................................................................190
Dendritic Cells in Tumor Immunology
..................................................................................191
Clinical Trials of Dendritic Cell-Based Vaccines
...................................................................193
Future Directions
.....................................................................................................................196
Conclusion
................................................................................................................................197
PART V. NOVEL TOPICS
16.
ANTIGEN-RECEPTOR GENE-MODIFIED
T
CELLS FOR TREATMENT OF
GLIOMA
............................................202
Hiroaki Ikeda and Hiroshi Shiku
Abstract
.....................................................................................................................................202
Introduction
..............................................................................................................................202
Interaction of Immune System with Central Nervous System
............................................203
Development of Specific Cancer Immunotherapy
................................................................204
Active Immunotherapy of Cancer..
..................................·.....·...·............·............·........·........ 204
Active Immunotherapy of Brain Tumor
................................................................................205
Passive Immunotherapy of Cancer
........................................................................................206
Antigen-Receptor Gene-Modified
T
Cells for Treatment of Cancer
...................................207
Passive Immunotherapy of Brain Tumor
..............................................................................211
Conclusion
................................................................................................................................211
xvüi CONTENTS
17.
GLIOMA
STEM CELL RESEARCH
FOR THE DEVELOPMENT OF IMMUNOTHERAPY
..........................216
Qijin Xu, Xiangpeng Yuan and John S. Yu
Abstract
.....................................................................................................................................216
Introduction..
.......·.........·.....................·................·.....·..·...·...........·........·.......«.·...·.·.·,·«..».·.·»·. 216
Glioma
Stem Cells as Cancer Initiating Cells
.......................................................................217
Targeting Brain Cancer Using Neural Stem Cell-Delivered Therapeutics
.........................218
Immunotherapy Strategies for GHomas and the Promise of Dendritic
Cell Vaccination
................................................................................................................220
Glioma
Stem Cell-Targeted Immunotherapy
........................................................................220
Conclusion
................................................................................................................................222
INDEX
........................................................................................................................227
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV040154757 |
| classification_rvk | XH 8565 |
| ctrlnum | (OCoLC)796245945 (DE-599)BVBBV040154757 |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01607nam a2200385 cb4500</leader><controlfield tag="001">BV040154757</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20120711 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">120525s2012 ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781461431459</subfield><subfield code="9">978-1-4614-3145-9</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)796245945</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV040154757</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-12</subfield><subfield code="a">DE-20</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 8565</subfield><subfield code="0">(DE-625)152960:13144</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Glioma</subfield><subfield code="b">immunotherapeutic approaches</subfield><subfield code="c">ed. by Ryuya Yamanaka</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York, NY</subfield><subfield code="b">Springer [u.a.]</subfield><subfield code="c">2012</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIX, 232 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Advances in experimental medicine and biology</subfield><subfield code="v">746</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Gliom</subfield><subfield code="0">(DE-588)4157618-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Immuntherapie</subfield><subfield code="0">(DE-588)4026640-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="8">1\p</subfield><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Gliom</subfield><subfield code="0">(DE-588)4157618-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Immuntherapie</subfield><subfield code="0">(DE-588)4026640-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamanaka, Ryuya</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Advances in experimental medicine and biology</subfield><subfield code="v">746</subfield><subfield code="w">(DE-604)BV000003102</subfield><subfield code="9">746</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025011410&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-025011410</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield></record></collection> |
| genre | 1\p (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV040154757 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T00:18:57Z |
| institution | BVB |
| isbn | 9781461431459 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-025011410 |
| oclc_num | 796245945 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-12 DE-20 |
| owner_facet | DE-355 DE-BY-UBR DE-12 DE-20 |
| physical | XIX, 232 S. Ill., graph. Darst. |
| publishDate | 2012 |
| publishDateSearch | 2012 |
| publishDateSort | 2012 |
| publisher | Springer [u.a.] |
| record_format | marc |
| series | Advances in experimental medicine and biology |
| series2 | Advances in experimental medicine and biology |
| spelling | Glioma immunotherapeutic approaches ed. by Ryuya Yamanaka New York, NY Springer [u.a.] 2012 XIX, 232 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Advances in experimental medicine and biology 746 Gliom (DE-588)4157618-4 gnd rswk-swf Immuntherapie (DE-588)4026640-0 gnd rswk-swf 1\p (DE-588)4143413-4 Aufsatzsammlung gnd-content Gliom (DE-588)4157618-4 s Immuntherapie (DE-588)4026640-0 s DE-604 Yamanaka, Ryuya Sonstige oth Advances in experimental medicine and biology 746 (DE-604)BV000003102 746 Digitalisierung UB Regensburg application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025011410&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Glioma immunotherapeutic approaches Advances in experimental medicine and biology Gliom (DE-588)4157618-4 gnd Immuntherapie (DE-588)4026640-0 gnd |
| subject_GND | (DE-588)4157618-4 (DE-588)4026640-0 (DE-588)4143413-4 |
| title | Glioma immunotherapeutic approaches |
| title_auth | Glioma immunotherapeutic approaches |
| title_exact_search | Glioma immunotherapeutic approaches |
| title_full | Glioma immunotherapeutic approaches ed. by Ryuya Yamanaka |
| title_fullStr | Glioma immunotherapeutic approaches ed. by Ryuya Yamanaka |
| title_full_unstemmed | Glioma immunotherapeutic approaches ed. by Ryuya Yamanaka |
| title_short | Glioma |
| title_sort | glioma immunotherapeutic approaches |
| title_sub | immunotherapeutic approaches |
| topic | Gliom (DE-588)4157618-4 gnd Immuntherapie (DE-588)4026640-0 gnd |
| topic_facet | Gliom Immuntherapie Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025011410&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000003102 |
| work_keys_str_mv | AT yamanakaryuya gliomaimmunotherapeuticapproaches |